看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
. ]; a/ z% `0 X6 [1 [3 q, T
1 r) \7 x; C9 T0 i0 m2 s4 l5 n0 r7 ~4 K* h- @) s. _8 f0 n
Currently available feasibility data for possible combination strategies. 4 W; X/ _* u- [& f! s
————————————————————————————————% H8 R1 E% e! l1 X
Combination Feasibility according to preliminary data
: H! Q$ B8 d+ ^) y% |7 F: m——————————————————————————————————0 C" K% f' C9 F: u1 H. Z* ]
Bevacizumab + sorafenib Yes, reduced dose 0 A4 E& y- c. Q! j5 v/ Z
Bevacizumab + sunitinib† No ( J) L+ y p6 u$ P& d0 h
Bevacizumab + temsirolimus Yes 4 [! ^, p% E; Q& N* F; ~+ \
Bevacizumab + everolimus Yes
( g; `+ a$ [+ z# o1 m1 sSorafenib + sunitinib ? 0 J6 N/ F) m; h& V4 e- w
Sorafenib + temsirolimus Yes, reduced dose + s& @9 s3 o8 Z' K+ `
Sorafenib + everolimus Yes, reduced dose
# X/ h E8 s8 {' e0 e) Z" e$ iSunitinib + temsirolimus† No
7 r7 _4 D \! y3 \, ?Sunitinib + everolimus ? - I6 J {. n$ C/ D: f
Temsirolimus + everolimus ?
& e9 P4 k0 `* N) K————————————————————4 D# @2 ^0 T8 B' Y
†Led to US FDA warning.
: o. `) F; e+ J; S Y3 v?: As yet unattempted combination.
( [- u$ t+ _% C1 A7 ^) f |